Cambridge Healthtech Institute’s 5th Annual

Rational Combination Cancer Immunotherapy

A Forward-Looking View of the Science and Strategies that Will Inform the Discovery and Development of Effective Immunotherapy Combinations
August 29-30, 2017 | Sheraton Boston Hotel | Boston, MA

The clinical and regulatory successes of checkpoint proteins are driving a resurgence of interest in immunotherapy as a primary form of cancer treatment, with numerous clinical studies exploring the application of these therapeutics in combinations with traditional and experimental agents. CHI’s 5th Annual Rational Combination Cancer Immunotherapy takes a forward-looking perspective on the design of drug products and treatment progressions that will build on the knowledge arising from these exploratory trials. The meeting will explore the scientific and strategic considerations for different immunotherapy combination strategies – and consider the business and clinical challenges facing research organizations wanting to successfully link their therapeutic programs to approved checkpoint inhibitors.

Preliminary Agenda

Keynote Presentation: Combination Cancer Immunotherapy: Current State and Future Opportunities

Jon Wigginton, M.D., CMO, Senior Vice President, Clinical Development, MacroGenics


CHALLENGES IN THE CLINICAL EVALUATION OF IMMUNOTHERAPY COMBINATIONS

Regulatory Perspectives on Early Clinical Development in a Combinatorial World

Elena Spanjaard, Ph.D., Director, Worldwide Research & Development, Regulatory Affairs, Pfizer

Trials Design Considerations for Immunotherapy Combinations: Selection of Patient Populations, Outcomes and Surrogate Endpoints

Susan R. Slovin, M.D., Ph.D., Medical Oncologist, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center


IMMUNOTHERAPY COMBINATION STRATEGIES

Four-Ingredient Antibody Cocktail for Cancer Immunotherapy

K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology

ADC Strategies for Cancer Immunotherapy

Dennis Benjamin, Ph.D., Vice President, Translational Research, Seattle Genetics, Inc.

Talk Title to be Announced

Sriram Sathy, Ph.D., Senior Director, Translational Sciences, Jounce Therapeutics

Risk Assessment Strategies for Immunotherapy Combinations: Should My PD-1/PD-l1 Backbone Come from a Partner or Via Internal Development?

Llew Keltner, M.D., Ph.D., CEO, EPISTAT

Application of Immunoscore to Rational Design of Immunotherapy Combinations

Brad Nelson, Ph.D., Director and Distinguished Scientist, Deeley Research Centre, BC Cancer Agency, Canada

Preclinical and Clinical Update: Immunotherapy Combination of Monoclonal Antibodies Fused to Immune Effector Molecules

Sanjay Khare, Ph.D., President, ImmunGene


TREATMENT PROGRESSION OF IMMUNOTHERAPY COMBINATIONS

Multidimensional Biomarker Analysis to Improve Immunotherapy

Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, Melanoma and Developmental Therapeutics Clinics, University of Chicago Medical Center

Prospects for Moving Treatments to Earlier in the Disease Progression

Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute

Emerging Immunotherapy Combinations in Non-Small Cell Lung Cancer

Justin F. Gainor, M.D., Instructor in Medicine, Massachusetts General Hospital


BIOMARKERS AND COMPANION DIAGNOSTICS

Evaluation of Current Progress in Discovering Biomarkers for Cancer Immunotherapy

Naveen Dakappagari, Ph.D., Senior Director, Immuno-Oncology Biomarker Development, Genoptix, a Novartis Company

Strategies for Development and Application of Companion Diagnostics to Support Immunotherapy Combinations

Vasiliki Pelekanou, M.D., Ph.D., Associate Research Scientist, Pathology, Yale University School of Medicine

Co-Development Issues for Immunotherapy Companion Diagnostics

Arnold Gelb, Ph.D., Head, Companion Diagnostic Development, EMD Serono, Inc.




For more details on the conference, please contact:
Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
207-869-9199
ksimmons@healthtech.com

For exhibit & sponsorship opportunities, please contact: 
 
Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today